NCT05965505

Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

An Open-Label, Multicenter, Phase I Study of AXT-1003 as a Single Agent in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Axter Therapeutics (Beijing) Co., Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in adult subjects with Relapsed/Refractory Non-Hodgkin Lymphomas.

Detailed description

The study is being conducted to assess the safety, tolerability, and pharmacokinetics (PK) of AXT-1003 in subjects with relapsed/refractory non-Hodgkin lymphomas (R/R NHL) and relapsed/refractory peripheral T-cell lymphoma (R/R PTCL), a subtype of R/R NHL.

Conditions

• Relapsed or Refractory Non-Hodgkin's Lymphoma

Interventions

Type	Name	Description
DRUG	AXT-1003	AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.

Timeline

• Start date: 2023-08-11
• Primary completion: 2023-09-05
• Completion: 2023-09-05
• First posted: 2023-07-28
• Last updated: 2024-08-01

Locations

4 sites across 1 country: China